NRXN1 and Parkinson disease: In Parkinson’s disease, treatment with Allopregnanolon (Allo) eliminated abnormalities in the electrophysiological aspects of synapses and abnormalities in the levels of the synaptic adhesion molecules PSD-95, neurexin-1, and neuroligins [56].